Increased risk of acute myocardial infarction in carriers of the hemochromatosis gene Cys282Tyr mutation: A prospective cohort study in men in eastern Finland

Circulation

Volumn 100, Issue 12, 1999, Pages 1274-1279

  Tuomainen, Tomi Pekka ^a   Kontula, Kimmo ^b   Nyyssönen, Kristiina ^a   Lakka, Timo A ^a   Heliö, Tiina ^b   Salonen, Jukka T ^a,c  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c NONE   (Finland)

Author keywords

Epidemiology; Hemochromatosis; Iron; Myocardial infarction

Indexed keywords

CYSTEINE; DNA; FERRITIN; IRON; TYROSINE;

ACUTE HEART INFARCTION; ADULT; ARTICLE; COHORT ANALYSIS; FINLAND; GENE; GENE FREQUENCY; GENE MUTATION; GENOTYPE; HEMOCHROMATOSIS; HETEROZYGOTE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK FACTOR;

EID: 0033592398     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.100.12.1274     Document Type: Article

References (36)

1. Witte DL, Crosby WH, Edwards CQ, Fairbanks VF, Mitros FA. Practice Guideline Development Task Force of the College of American Pathologists: hereditary hemochromatosis. Clin Chim Acta. 1996;245:139-200.
2. Edwards CQ, Griffen LM, Goldgar D, Drummond C, Skolnick MH, Kushner JP. Prevalence of hemochromatosis among 11,065 presumably healthy blood donors. N Engl J Med. 1988;318:1355-1362.
3. Edwards CQ, Kushner JP. Screening for hemochromatosis. N Engl J Med. 1993;328:1616-1620.
4. Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, Dormishian F, Domingo R Jr, Ellis MC, Fullan A, Hinton LM, Jones NL, Kimmel BE, Kronmal GS, Lauer P, Lee VK, Loeb DB, Mapa FA, McClelland E, Meyer NC, Mintier GA, Moeller N, Moore T, Morkang E, Prass CE, Drayna DT, Risch NJ, Bacon BR, Wolff RK. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet. 1996;13:399-408.
5. Salonen JT, Nyyssönen K, Korpela H, Tuomilehto J, Seppänen R, Salonen R. High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation 1992;86: 803-811.
6. Tuomainen T-P, Punnonen K, Nyyssönen K, Salonen JT. Association between body iron stores and the risk of acute myocardial infarction in men. Circulation. 1998;97:1461-1466.
7. Salonen JT. Is there a continuing need for longitudinal epidemiologic research? The Kuopio Ischaemic Heart Disease Risk Factor Study Ann Clin Res. 1988;20:46-50.
8. Syvänen A-C, Aalto-Setälä K, Harju L, Kontula K, Söderlund H. A primer-guided nucleotide incorporation assay in the genotyping of apolipoprotein E. Genomics. 1990;8:684-692.
9. Salonen JT, Seppänen K, Nyyssönen K, Korpela H, Kauhanen J, Kantola M, Tuomilehto J, Esterbauer H, Tatzber F, Salonen R. Intake of mercury from fish, lipid peroxidation, and the risk of myocardial infarction and coronary, cardiovascular, and any death in eastern Finnish men. Circulation. 1995;91:645-655.
10. Nyyssönen K, Parviainen MT, Salonen R, Tuomilehto J, Salonen JT. Vitamin C deficiency and risk of myocardial infarction: prospective population study of men from eastern Finland. BMJ. 1997;314:634-638.
11. Salonen JT, Nyyssönen K, Tuomainen T-P, Mäenpää PH, Korpela H, Kaplan GA, Lynch J, Helmrich SP, Salonen R. Increased risk of non-insulin dependent diabetes mellitus at low plasma vitamin E concentrations: a four year follow-up study in men. BMJ. 1995;311:1124-1127.
12. Puhakainen EVJ, Barlow RD, Salonen JT. An automated colorimetric assay for urine nicotine metabolites: a suitable alternative to cotinine assays for the assessment of smoking status. Clin Chim Acta. 1987;170: 255-262.
13. Tuomilehto J, Kuulasmaa K. WHO MONICA Project: assessing CHD mortality and morbidity. Int J Epidemiol. 1989;18:S38-S45.
14. Mura C, Nousbaum J-B, Verger P, Moalic MT, Raguenes O, Mercier AY, Ferec C. Phenotype-genotype correlation in haemochromatosis subjects Hum Genet. 1997;101:271-276.
15. Adams PC, Chakrabarti S. Genotypic/phenotypic correlations in genetic hemochromatosis: evolution of diagnostic criteria. Gastroenterology. 1998;114:319-323.
16. Merryweather-Clarke AT, Pointon JJ, Shearman JD, Robson KJ. Global prevalence of putative haemochromatosis mutations. J Med Genet. 1997; 34:275-278.
17. Karlsson M, Ikkala E, Reunanen A, Takkunen H, Vuori E, Mäkinen J. Prevalence of hemochromatosis in Finland. Acta Med Scand. 1988;224: 385-390.
18. 2-microglobulin interaction and cell surface expression. J Biol Chem. 1997;272: 14025-14028.
19. Zhou XY, Tomatsu S, Fleming R, Parkkila S, Waheed A, Jiang J, Fei Y, Brunt EM, Ruddy DA, Prass CE, Schatzman RC, O'Neill R, Britton RS, Bacon BR, Sly WS. HFE gene knockout produces mouse model of hereditary hemochromatosis. Proc Natl Acad Sci U S A. 1998;95: 2492-2497.
20. Feder JN, Penny DM, Irrinki A, Lee VK, Lebron JA, Watson N, Tsuchihashi Z, Sigal E, Björkman PJ, Schatzman RC. The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding. Proc Natl Acad Sci U S A 1998;95: 1472-1477.
21. 2-microglobulin, intracellular processing, and cell surface expression of the HFE protein in COS-7 cells. Proc Natl Acad Sci U S A. 1997;94: 12384-12389.
22. Tuomainen T-P, Salonen R, Nyyssönen K, Salonen JT. Cohort study of ; relation between donating blood and risk of myocardial infarction in 2682 : men in eastern Finland. BMJ. 1997;314:793-794.
23. Salonen JT, Tuomainen T-P. Salonen R, Lakka TA, Nyyssönen K. Donating blood is associated with a reduced risk of myocardial infarction: the Kuopio Ischemic Heart Disease Risk Factor Study (KIHD). Am J Epidemiol. 1998;148:445-451.
24. Salonen JT. The role of iron as a cardiovascular risk factor. Curr Opin Lipidol. 1993;4:277-282.
25. Salonen JT. Body iron stores, lipid peroxidation and coronary heart disease. In: Hallberg L, Asp N-G, eds. Iron Nutrition in Health and Disease. London, UK: JL London Press; 1996:293-301.
26. Smith C, Mitchinson MJ, Aruoma OI, Halliwell B. Stimulation of lipid peroxidation and hydroxyl-radical generation by the contents of human atherosclerotic lesions. Biochem J. 1992;286:901-905.
27. Swain J, Gutteridge JM. Prooxidant iron and copper, with ferroxidase and xanthine oxidase activities in human atherosclerotic material. FEBS Lett. 1995;368:513-515.
28. Lee FY, Lee TS, Pan CC, Huang AL, Chau LY. Colocalization of iron and ceroid in human atherosclerotic lesions. Atherosclerosis. 1998;138: 281-288.
29. Ambrosio G, Zweier JL, Jacobus WE, Weisfeldt ML, Flaherty JT. Improvement of postischemic myocardial function and metabolism induced by administration of deferoxamine at the time of reflow: the role of iron in the pathogenesis of reperfusion injury. Circulation. 1987;76: 906-915.
30. Farber NE, Vercellotti GM, Jacob HS, Pieper GM, Gross GJ. Evidence for a role of iron-catalyzed oxidants in functional and metabolic stunning in the canine heart. Circ Res. 1988;63:351-360.
31. Nassar BA, Zayed EM, Title LM, O'Neill BJ, Bata IR, Kirkland SA, Dunn J, Dempsey GI, Tan MH, Johnstone DE. Relation of HFE gene mutations, high iron stores and early onset coronary artery disease. Can J Cardiol. 1998;14:215-220.
32. Franco RF, Zago MA, Trip MD, ten Cate H, van den Ende A, Prins MH, Kastelein JJ, Reitsma PH. Prevalence of hereditary haemochromatosis in premature atherosclerotic vascular disease. Br J Haematol. 1998;102: 1172-1175.
33. Adams PC. Prevalence of abnormal iron studies in heterozygotes for hereditary hemochromatosis: an analysis of 255 heterozygotes. Am J Hematol. 1994;45:146-149.
34. Bulaj ZJ, Griffen LM, Jorde LB, Edwards CQ, Kushner JP. Clinical and biochemical abnormalities in people heterozygous for hemochromatosis. N Engl J Med. 1996;335:1799-1805.
35. Niederau C, Fischer R, Sonnenberg A, Stremmel W, Trampisch HJ, Strohmeyer G. Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N Engl J Med. 1985;313: 1256-1262.
36. Sullivan JL. Heterozygous hemochromatosis as a risk factor for premature myocardial infarction. Med Hypotheses. 1990;31:1-5.